Mostrar el registro sencillo del ítem
dc.contributor.author
Perroud, Herman Andrés
dc.contributor.author
Scharovsky, Olga Graciela
dc.contributor.author
Rozados, Viviana Rosa
dc.contributor.author
Alasino, Carlos
dc.date.available
2022-11-25T17:10:19Z
dc.date.issued
2017-03
dc.identifier.citation
Perroud, Herman Andrés; Scharovsky, Olga Graciela; Rozados, Viviana Rosa; Alasino, Carlos; Clinical response in patients with ovarian cancer treated with metronomic chemotherapy; Cancer Intelligence; Ecancermedicalscience; 11; 723; 3-2017; 1-10
dc.identifier.issn
1754-6605
dc.identifier.uri
http://hdl.handle.net/11336/179068
dc.description.abstract
Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Cancer Intelligence
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by/2.5/ar/
dc.subject
OVARIAN CANCER
dc.subject
METRONOMIC CHEMOTHERAPY
dc.subject
CYCLOPHOSPHAMIDE
dc.subject.classification
Otras Ciencias Biológicas
dc.subject.classification
Ciencias Biológicas
dc.subject.classification
CIENCIAS NATURALES Y EXACTAS
dc.title
Clinical response in patients with ovarian cancer treated with metronomic chemotherapy
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2022-11-24T13:19:28Z
dc.journal.volume
11
dc.journal.number
723
dc.journal.pagination
1-10
dc.journal.pais
Reino Unido
dc.journal.ciudad
Bristol
dc.description.fil
Fil: Perroud, Herman Andrés. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Instituto Universidad Italiano de Rosario; Argentina
dc.description.fil
Fil: Scharovsky, Olga Graciela. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina. Universidad Nacional de Rosario. Consejo de Investigaciones de la Universidad de Rosario; Argentina
dc.description.fil
Fil: Rozados, Viviana Rosa. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico Conicet - Rosario; Argentina. Universidad Nacional de Rosario. Facultad de Ciencias Medicas. Instituto de Genetica Experimental; Argentina
dc.description.fil
Fil: Alasino, Carlos. Instituto de Oncología de Rosario; Argentina. Instituto Universidad Italiano de Rosario; Argentina
dc.journal.title
Ecancermedicalscience
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/ 10.3332/ecancer.2017.723
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://ecancer.org/en/journal/article/723-clinical-response-in-patients-with-ovarian-cancer-treated-with-metronomic-chemotherapy
Archivos asociados
Tamaño:
517.3Kb
Formato:
PDF